Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of ocular disease Contrary to historical studies of CBD, CBDVHS was not associated with an elevation in intraocular pressure Long Beach, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address g
June 9, 2020
· 4 min read